Immunoglobulin Market Overview:
Global Immunoglobulin Market was valued at $8,374 million in 2016, and is projected to reach $13,619 million by 2023, registering a CAGR of 7.3% from 2017 to 2023. Immunoglobulin is a protein produced by plasma cells and other lymphocytes. They are highly complex entities that exert their immunomodulatory effect on the different components of the immune system. They are obtained from blood by fractionation process and purified for therapeutic and non-therapeutic applications. Different classes of immunoglobulin such as IgG, IgA, and IgM are used for the treatment of various immunological and neurological diseases. These immunoglobulins can be administered intravenously and subcutaneously.
Global Immunoglobulin Segmentation
The report segments the global immunoglobulin market based on application, product type, mode of delivery, and concentration. Applications covered in the study include hypogammaglobulinemia, CIDP, immunodeficiency diseases, myasthenia gravis, multifocal motor neuropathy, idiopathic thrombocytopenic purpura (ITP), inflammatory myopathies, specific antibody deficiency, GBS, and others. Based on product type, the market is segmented into immunoglobulin G (IgG), IgA, IgM, IgE, and IgD. By mode of delivery, it is bifurcated into intravenous and subcutaneous. Intravenous mode of delivery is further categorized into 5%, 10%, and other concentration. Subcutaneous mode of delivery is further classified into 16.5%, 20%, and other concentration.
The market is expected to witness a moderate growth during the forecast period, owing to Increase in geriatric population & number of hemophilic patients, improved immunoglobulin production owing to the emergence of advanced technologies, and enhanced purification techniques (with better plasma yield). Furthermore, surge in prevalence of chronic inflammatory demyelinating polyneuropathy (CIDP) & hypogammaglobulinemia and rise in use of immunoglobulins to treat Guillain-Barre syndrome (GBS), inflammatory myopathies, specific antibody deficiency, and others, are expected to boost the market growth. However, stringent government regulations toward immunoglobulin products, expensive therapy, and high risk of side effects associated with the use of immunoglobulin are expected to hamper this market growth.
The report provides extensive competitive analysis and profiles of key market players that includes Baxter international Inc., CSL Ltd., Grifols S.A, Octapharma AG, Kedrion Biopharma Inc., LFB group, Biotest AG, China Biologics Products, Inc., BDI Pharma Inc., and Bayer Healthcare.
Other players in the value chain include Hualan Biological Engineering Inc., Omrix Biopharmaceuticals Ltd., Behring GmbH, Shanghai RAAS Blood Products Co., Ltd., Option Care Enterprises, Inc., ADMA Biologics, Inc., and BioScrip, Inc.
Immunoglobulin Market, by Geography, 2016-2023 ($Million)
North America is the largest contributor toward the global market, followed by Asia-Pacific. These regions collectively occupy almost 75% of the global market revenue. Presence of the largest plasma production facilities and high adoption rate in the developed countries majorly boost the market growth.
India Immunoglobulin Market, 2016-2023 ($Million)
India immunoglobulin market is projected to grow at a CAGR of 8.1% during the forecast period.
This report entails a detailed quantitative analysis of the current market trends from 2016 to 2023 to identify the prevailing opportunities.
Market estimations are based on comprehensive analysis of the key developments in the industry.
The global market is comprehensively analyzed with respect to products type, application, mode of delivery, and geography.
In-depth analysis based on geography assists in understanding the regional market to assist in strategic business planning.
The development strategies adopted by key manufacturers are enlisted to understand the competitive scenario of the market.
Immunoglobulin Market Key Segments:
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Immunodeficiency Diseases
- Myasthenia Gravis
- Multifocal Motor Neuropathy
- Idiopathic Thrombocytopenic Purpura (ITP)
- Inflammatory Myopathies
- Specific Antibody Deficiency
- Guillain-Barr Syndrome
By Mode of Delivery
- 5% Concentration
- 10% Concentration
- 16.5% Concentration
- 20% Concentration
- North America
- Rest of Europe
- Rest of Asia-Pacific
- Saudi Arabia
- Rest of LAMEA